sellWeak10b5-1 plan
Buscemi Stephanie sold $4.3M of CFLT
CHIEF MARKETING OFFICER at Confluent, Inc.. 164,123 shares at an average of $26.24, traded Nov 1, 2024, filed Nov 5, 2024.
Warning score
25Value
$4.3M
164,123 shares
Holdings after
149,644
-52% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-026202, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 1, 2024 | CConversion Class A Common Stock10b5-1 | +152,094 | - | - | 313,767 | Nov 5, 2024 |
| Nov 1, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -164,123 | $26.24 | $4.3M | 149,644 | Nov 5, 2024 |
| Nov 1, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -152,094 | $0.00 | $0 | 785,598 | Nov 5, 2024 |
| Nov 1, 2024 | MOption exercise Class B Common Stockderivative10b5-1 | +152,094 | $0.00 | $0 | 152,094 | Nov 5, 2024 |
| Nov 1, 2024 | CConversion Class B Common Stockderivative10b5-1 | -152,094 | $0.00 | $0 | 0 | Nov 5, 2024 |
Related signals
Other insiders at Confluent, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 48Moderate | sell 210b5-1 | CFLT Confluent, Inc. | Caimi Lara director | $1.1M | 34,500 | |
| 48Moderate | sell 210b5-1 | CFLT Confluent, Inc. | Chadwick Jonathan director | $1.1M | 34,375 | |
| 15Weak | sell10b5-1 | CFLT Confluent, Inc. | Buscemi Stephanie CHIEF MARKETING OFFICER | $1.6M | 48,953 | |
| 26Weak | sell | CFLT Confluent, Inc. | Buscemi Stephanie CHIEF MARKETING OFFICER | $149k | 5,271 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.